Skip to main content
Premium Trial:

Request an Annual Quote

ConcertAI Acquires ASCO's Real-World Oncology Data Platform CancerLinq

NEW YORK – ConcertAI on Monday announced it has acquired CancerLinq, a real-world data platform that the American Society of Clinical Oncology launched a decade ago to improve oncology research.

Cambridge, Massachusetts-based ConcertAI, which provides real-world evidence and generative artificial intelligence solutions, said it will invest $250 million to enhance CancerLinq's use of real-world data, machine learning, analytics, and other advanced technologies so that users can continue to improve cancer care and research with it. While the organizations didn't disclose the financial terms of the acquisition, they said that ASCO will remain involved in improving the platform via a multiyear cooperation agreement with CancerLinq.

Since its launch, CancerLinq has amassed clinical data from nearly 7 million patient records housed within various electronic medical record (EMR) systems at more than 100 cancer centers and oncology practices. The platform has compiled, harmonized, and analyzed de-identified clinical data, including the treatments patients are on, their molecular profiles, and their outcomes.

Now under ConcertAI, CancerLinq will continue to focus on improving the quality of cancer care, advancing the principles of precision medicine, expanding real-world datasets for research, and supporting a new clinical trials initiative evolving from its TriaLinq concepts, according to a statement from ASCO and ConcertAI. 

ConcertAI will also work with ASCO to enhance clinical trial data by drawing on new data sources, make clinical trials more accessible and reduce the burden on participants, develop clinical decision support, and enable automated EMR integration.

"We believe this agreement will provide the resources to fulfill and amplify CancerLinq's impact, while allowing ASCO to harness the CancerLinq platform for quality improvement initiatives and CancerLinq Discovery data for research to support our mission," said ASCO CEO Clifford Hudis in a statement, adding that the organization expects CancerLinq can also help cancer centers that want recognition as a patient-centered value-based care provider under its recently launched ASCO Certified program.